Drug price control unilateral, rationale puzzling: Biocon
Indian pharma’s brand value being eroded and brand-building must be allowed in India says Kiran Mazumdar, Biocon. Disappointed with NDA govt’s decision on drug price control, she further added.
Other Corporate Videos
TCS screening candidates for C-suite rejig ahead; COO, CTO posts to be filled soon
Unicorn ed-tech firm Byju's lays off at least 1,000 more employees across various functions
Tata Trusts appoints Siddharth Sharma as CEO, Aparna Uppaluri as COO
Government to release standards for checking fake reviews on e-commerce, other platforms
Reliance retail, Adani group companies among bidders for Future Retail
